Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Atanaz Zargar
Total Records ( 2 ) for Atanaz Zargar
  Lindsey Childress , Andrea Gay , Atanaz Zargar and Matthew K. Ito
 

Background

Red yeast rice (RYR) is a commonly used dietary supplement for the management of dyslipidemia. In 2007, the Food and Drug Administration (FDA) issued a consumer warning to avoid RYR products because they may contain unauthorized drug (lovastatin) and also implemented Current Good Manufacturing Practices (CGMP) requiring that proper controls be in place by dietary supplement companies to ensure products are manufactured and processed in a consistent manner and produce high-quality products that are not adulterated with impurities or contaminants and are accurately labeled.

Objective

To assess the FDA oversight of companies manufacturing RYR products and review the labeled content of available RYR products.

Methods

The FDA was audited through the Freedom of Information Act, we requested answers to a series of questions concerning their oversight of companies manufacturing RYR products. The labeled content of each RYR product listed in the Natural Medicines Comprehensive Database (NMCD) was tabulated and summarized. Statin-related product warnings and if product certification and verification by an independent laboratory had been performed were documented.

Results

The FDA had no information on the number of RYR manufacturers and their compliance with CGMP regulations. A total of 101 products containing RYR were reviewed. No product could be confirmed as passing any independent laboratory verification testing. Nearly one-half (42.6%) of the RYR product labels contained statin-related warnings (ie, potential for muscle pain or weakness, etc).

Conclusion

Currently, the FDA is not regulating manufacturers of RYR products and as a result, many of these products may contain monacolin K and toxins such as citrinin.

  Atanaz Zargar , Clint Auttapibarn , Sung Hee Hong , Tyler J. Larson , Katelyn H. Hayworth and Matthew K. Ito
 

Background

Many patients drink cafe latte as part of their habitual morning routine to start their day and may be unable to skip this step before drawing a fasting blood sample for cholesterol testing. However, it is unknown what the acute effects of consuming a cafe latte are on fasting serum lipids just before blood sampling.

Objective

This was a prospective, open-label study with the primary objective of evaluating the acute effect of a 12-oz cafe latte (2% milk) on calculated low-density lipoprotein cholesterol (LDL-C) and secondary objectives of triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and fasting blood glucose (FBG).

Methods

A 10-hour fasting lipid profile was obtained before and 30 minutes after subjects consumed the cafe latte.

Results

Forty-nine adult participants (34 females; age [mean ± SD] 32.2 ± 13.2 years) were studied. No significant changes in total cholesterol, LDL-C, or non-HDL-C were observed after coffee consumption. Triglyceride significantly decreased from a median of 76.0 to 75.0 mg/dL (P = .002). HDL-C and FBG increased from a mean of 54.4 ± 12.7 to 56.4 ± 14.5 mg/dL (P = .015) and 87.2 ± 7.0 to 97.3 ± 12.9 mg/dL (P < .001), respectively.

Conclusion

Consumption of 12 oz. of cafe latte within one hour of blood draw did not result in a significant change in LDL-C or non-HDL-C in young, nonobese healthy individuals. However, FBG levels increased by almost 12%.

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility